MOTS-c vs Pinealon
Both MOTS-c and Pinealon are used for longevity. Here's how their evidence, dosing, and regulatory status actually compare.
MOTS-c
Evidence BMitochondrial-derived peptide MOTS-c
A 16-amino-acid mitochondrial-derived peptide that improves insulin sensitivity and exercise capacity in animal models. Among the most promising 'mitokines' for metabolic aging.
View full MOTS-c profile →Pinealon
Evidence CPinealon (EDR)
A short tripeptide developed in Russia for cognitive aging and oxidative stress. Limited Western clinical evidence.
View full Pinealon profile →Side-by-Side
| Attribute | MOTS-c | Pinealon |
|---|---|---|
| Evidence Grade | B | C |
| FDA Status | Not FDA-approved — research peptide; multiple early-phase clinical trials | Not FDA-approved — Russian-origin research peptide |
| Typical Dose | 5–10 mg, 2–3 times weekly (subcutaneous) | 5–10 mg daily for 10–20 days (subcutaneous, cycled) |
| Clinics Indexed | 22 | 9 |
| Categories | metabolic, longevity | cognitive, longevity |
Key reported benefits — MOTS-c
- ✓Insulin sensitivity
- ✓Exercise capacity
- ✓Metabolic flexibility
Key reported benefits — Pinealon
- ✓Cognitive function (preclinical)
- ✓Reduced oxidative damage
- ✓Sleep/circadian effects
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.